Introduction
Over the last two decades, health-related quality of life-and the related concept of 'health status'-has increasingly been used as an outcome measure in clinical trials and comparative effectiveness research. outcomes such as health status to support labelling claims. 7 In heart failure (HF), the Kansas City Cardiomyopathy Questionnaire (KCCQ) is one of the most commonly used and rigorously studied instruments for quantifying health status, having been validated in multiple HF-related disease states. 8 -11 In fact, baseline health status measured by the KCCQ predicts HF prognosis, and the U.S. Food and Drug Administration is considering the KCCQ for official recognition as a validated clinical outcome for HF.
12 -14 Interpreting the clinical meaning of statistically significant changes in health status measures, however, remains relatively unknown. A 5-point change in KCCQ overall summary score is widely considered to be the minimally noticeable clinical difference experienced by patients. 4,15 -17 In an observational cohort of 476 outpatients with HF followed over a 6-week period, a mean of -5.4 ±10.8 points and + 5.7 ±16.1 points corresponded to the treating cardiologist's assessment of a small deterioration or improvement in HF, respectively. 18 Change was determined by the physician's assessment of whether a patient's health status had changed based on a single 7-point scale question: large, moderate, or small deterioration; no change; or small, moderate, or large improvement. In the same analysis, patients deemed changes of as many as 1 to 5 KCCQ points to be clinically meaningful. 19 In recent randomized trials, HF interventions from ivabradine to sacubitril/valsartan have been associated with small changes in health status from 1 to 3 KCCQ points. 5, 14 To better characterize the potential clinical benefit associated with smaller changes in health status, we used data from Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) to describe patient groups who experienced a change in health status from baseline to 3 months and estimated the relationship between changing health status and subsequent clinical outcomes.
Methods
The study design and primary results of HF-ACTION have been previously published. 4, 20 HF-ACTION remains the largest multicentre, randomized clinical trial to have investigated the safety and efficacy of aerobic exercise training compared to optimal medical therapy -in combination or alone -in ambulatory patients with reduced ejection fraction (≤35%) and New York Heart Association (NYHA) class II-IV symptoms. The primary endpoint was a composite of all-cause death or all-cause hospitalization, and secondary endpoints included all-cause death and cardiovascular death or HF hospitalization. Exercise training consisted of supervised aerobic exercise (walking, treadmill, or stationary cycling) three times weekly for 36 sessions, followed by transition to a home-based exercise programme. Follow-up occurred over a median of 2.6 years. The protocol was approved by the institutional review board or ethics committee at each of the 82 participating clinical study centres and the coordinating centre. All patients provided written informed consent.
In HF-ACTION, the KCCQ questionnaire was used to measure HF-specific health status. 8 The KCCQ transforms patient answers to 23 Likert-scale items into a 0 to 100-scaled overall summary score. Higher scores represent better health status. Several health domains specific to HF patients are tested including physical functioning, symptom frequency and severity, social function, self-efficacy, and overall quality of life. Patients self-administered the KCCQ at the baseline visit, at 3-month intervals for the first 12 months, and annually thereafter for up to 4 years. However, despite the protocol, there was increasing missingness in KCCQ data capture after the 3-month visit. Additionally, patients separated by treatment group did not experience significant changes in KCCQ after 3 months. 4 21 We categorized change in KCCQ overall summary score from baseline to 3 months as decrease (≥5 point decrease), no change (absolute change <5 points), and increase (≥5 point increase). We describe baseline characteristics by the categorized change from baseline to 3 months. Categorical variables were presented as frequencies and percentages, and continuous variables were reported as medians with 25th and 75th percentiles. We compared baseline differences using the Kruskal-Wallis test for continuous variables and Pearson chi-square or Fisher's exact tests for categorical variables.
Cox proportional hazards models were used to assess the association between change in KCCQ overall summary score (as a continuous independent variable) and rate of clinical outcomes. These analyses were landmarked at the 3-month visit. We tested the proportional hazards assumption and the linearity assumption for the change in KCCQ overall summary score. To assess the linearity assumption, we modelled the relationship between change in KCCQ summary score and outcomes using restricted cubic splines. The linearity assumption was not satisfied. To aid in interpretability, we modelled the non-linear relationship between change in KCCQ summary score and outcomes using piecewise linear splines with a single knot at the value of 8 for the change in KCCQ summary score. This knot value was selected by fitting the model over a range of potential knots, and selecting the model that had the lowest Akaike Information Criteria. To examine the robustness of the association, we employed three nested adjustment models: Model 1 -unadjusted; Adjusted Model 2 -adjusted for baseline KCCQ overall summary score; and Adjusted Model 3 -Model 2 in addition to randomized treatment assignment and additional clinical covariates known to predict outcomes in HF-ACTION. 22 Additional sensitivity analyses were performed with KCCQ change from 3 to 6 months to study these associations at a more stable time period after clinical trial enrolment.
Given the clinical interpretability of a 5-point change to represent minimal change, we also used multivariable Cox proportional hazards models to assess the association between change in KCCQ summary score as a categorical variable (≥5 point improvement, ≥5 point deterioration, and < 5 point change) and risk of clinical outcomes. In addition to estimating hazard ratios (HR) and 95% confidence intervals (CI), two-sided tests were also conducted at a significance level of 0.05. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).
Results
This analysis included 2038 patients with complete KCCQ data at baseline and 3 months. Patients who experienced an event in the first 3 months were excluded from the analysis (n = 293). Online supplementary Table S1 compares the characteristics between patients excluded and included in the primary analysis. There were minor differences between the populations. Excluded patients were more likely to be African American (42.9% vs. 31.1%), less likely to have an implantable cardioverter-defibrillator (32.1% vs. 41.4%), and reported lower KCCQ summary scores (62 vs. 69).
In the analysis population, the median baseline KCCQ overall summary score was 69 (Q1-Q3 52-83). From baseline to 3 months, 918 patients (45%) experienced a ≥ 5 point improvement in health status, while 23% (n = 462) experienced a ≥ 5 point decline, and 32% (n = 658) experienced a change of less than 5 points. The distribution of patients' KCCQ overall summary scores at 3 months and as a change from baseline to 3 months is presented in Figure 1 . Overall, 215 (11%) patients experienced a change between +5 to +8 KCCQ points, and 703 (35%) patients experienced an improvement in KCCQ overall score above 8 points. rate, body mass index and history of atrial fibrillation and renal dysfunction, but most of these differences were not clinically meaningful. A higher proportion of patients who experienced improvement in KCCQ were assigned baseline NYHA class III-IV symptom limitations compared to those who reported minimal change (39.5% vs. 31.2%). Baseline functional capacity as measured by peak oxygen consumption was not significantly different among the three groups (median 14.5 mL/kg/min). 
Figure 3
Relationship between change in Kansas City Cardiomyopathy Questionnaire (KCCQ) at 3 months and all-cause mortality or hospitalization. Among patients event-free at 3 months, this plot demonstrates the non-linear relationship between 3-month change in KCCQ overall summary score and predicted probability of all-cause death or hospitalization within 3 years. In our data, we observe a single inflection point where change in KCCQ is equal to 8. Increases in KCCQ from 0 to 8 was associated with a significant reduction in risk (P < 0.001) but increases in KCCQ greater than 8 were not significantly associated with an increase in risk (P = 0.18). Vertical reference bars identify these inflection points. Decreases in KCCQ between baseline and 3 months was associated with increased risk (P < 0.001). Solid line indicates the predicted probability of death/hospitalization; dotted line indicates point-wise 95% confidence intervals.
of death or hospitalization than patients with minimal change (72.1% vs. 67.5%; P = 0.004). However, rates were similar between patients who reported a ≥ 5 point improvement and those with <5 point change (68% vs. 67.5%). Similarly, rates of all-cause death and cardiovascular death or HF hospitalization were greatest among patients reporting a KCCQ decline compared to those with no change or a KCCQ increase. Figure 3 shows the non-linear relationship between change in KCCQ and all-cause death or hospitalization. In unadjusted analysis, improvement in KCCQ up to 8-point increase was associated with lower risk of clinical outcomes (HR 0.91 per 5-point increase in KCCQ up to 8; 95% CI 0.88-0.95; P < 0.001); larger increases above 8 points were not associated with a change in risk of clinical outcomes (Table 2; Figure 2 ). Worsening KCCQ was associated with an increased risk of death or hospitalization (HR 1.10 per 5-point decrease in KCCQ; 95% CI 1.06-1.14; P < 0.001). After adjustment for randomized treatment assignment, baseline KCCQ score, and other clinical covariates found to predict outcomes in this trial population, overall results were similar. 22 The modelling of the other cardiovascular endpoints demonstrated similar overall relationships ( Table 2) . Additional sensitivity analyses evaluating KCCQ change between the 3-and 6-month interval also demonstrated a non-linear and similar overall risk relationships (online supplementary Table S2 ). In analyses evaluating the association between categorized change in KCCQ and risk of clinical outcomes, those experiencing a decline in health status had significantly higher risk of death or hospitalization, all-cause death, and cardiovascular mortality or HF hospitalization in unadjusted analyses (Table 3; Figure 2 ). However, after adjustment for clinical variables, while a consistent trend for increased risk persisted across all endpoints, the association was only statistically significant between health status decline and cardiovascular mortality or HF hospitalization (adjusted HR 1.36; 95% CI 1.06-1.76; P = 0.02). In contrast, the group of patients reporting a ≥ 5 point improvement in KCCQ experienced similar rates of death or hospitalization as patients reporting minimal change (unadjusted HR 1.0; 95% CI 0.86-1.17; P = 0.99; adjusted HR 0.88; 95% CI 0.74-1.04; P = 0.12). There was no significant interaction between change in KCCQ and outcomes by randomized treatment assignment (P = 0.22 for all-cause death/hospitalization). Associations between baseline KCCQ overall summary score at 3 months and outcomes are available in the online supplementary Table S3 .
Discussion
Prior studies have shown the sensitivity of KCCQ to reflect clinical change and risk for clinical outcomes in individual patients with HF. and 8 points was associated with a similar reduction in risk of future outcomes. However, larger short-term improvements in KCCQ above 8 points were no longer associated with any further risk reduction. These results extend our understanding of KCCQ as a tool to prognosticate disease in HF, especially for patients at risk for decompensation.
Patient-reported quality of life as it relates to health-or health status-encompasses broad concepts of physical and social functioning, mental and general health, as well as overall perceptions of energy or vitality, pain, and cognitive function. Adding to the complexity, these factors can be influenced by varying personal values, preferences, and motivation, as well as available psychological and social support. 23 Our results support prior findings that the KCCQ measures patient features not captured by traditional clinical variables.
13,17
Prior authors have evaluated serial KCCQ measurement changes over 2 months and shown its association with mortality in the EPHESUS clinical trial population of patients with HF after a myocardial infarction. 24 In that population, each 5-point decrease in KCCQ was associated with an 11% increased risk of 1-year all-cause mortality. Our analysis corroborates and expands these results to a wider population of stable outpatients with HF and with longer follow-up. In contrast, though, our analysis suggests a non-linear relationship in how changing KCCQ predicts future adverse events.
In our analysis, declines in KCCQ were consistently associated with increased risk. Patients experiencing a decline in health status showed some trends for having greater disease severity (higher median N-terminal B-type natriuretic peptide markers, higher likelihood of having atrial fibrillation, and worse renal function) but differences were modest. They also reported fair baseline health status by KCCQ, where a median score of 74 has been shown to be associated with NYHA class II symptoms in prior reports. 13 In these patients, a decline in KCCQ may serve as a more reliable prognosticator of clinical worsening and need for heightened monitoring, as previously prescribed by other authors. 13, 24 In clinical settings where the signal to noise ratio of patient data is declining, the consistency of this relationship suggests that 'declining KCCQ score' has value as an actionable risk assessment.
In our analysis, experiencing an improvement in KCCQ score from 0 to 8 was associated with a significant reduction in risk of future adverse outcomes. However, with larger degrees of positive change (8 KCCQ points in our sample), we no longer show a prognostic relationship. Given the subjective and qualitative nature of improving health status, large improvements may have incrementally smaller effects on future outcomes, suggesting a theoretical 'ceiling effect'. This non-linear relationship has not been seen in other analyses and requires better characterization in other populations. In our study population, important differences differentiated patients who experienced ≥5 point improvement from other groups. Patients who experienced ≥5 point improvement had the lowest median baseline KCCQ scores by 20 points compared to the minimal change group; prior research estimated a discrepancy of around 30 points to be associated with the difference between NYHA class I and class III symptoms. 13 a 5-point change in the KCCQ overall summary score is widely recognized to be the minimally noticeable clinical difference and prognostic of future events. Recent randomized trials studying HF interventions have reported KCCQ changes in the range of 1-5 points. 4, 5, 14 More analysis is necessary to better discriminate how patients interpret these small KCCQ changes. In the context of our current analysis, this study suggests changes smaller than a 5-point improvement may be prognostic of clinical outcomes. For clinical trials that use HF health status as primary or secondary outcomes, these observations have important implications.
We make note of potential limitations in this analysis. First, HF-ACTION represents a clinical trial population of disproportionately younger and more male patients with HF; some selection bias is inherent. Second, patients responded to serial health status surveys in this analysis in the setting of a clinical trial. While it is uncertain if our findings will generalize to a different clinical setting, recent systematic reviews have not supported the idea that patients enrolled in clinical trials receive inherently better care. 26 Third, a smaller proportion of patients experienced large magnitudes of change, which may have limited our power to define the association of improvements in KCCQ with outcomes. Fourth, while we adjusted for multiple clinical factors known to predict outcomes in HF-ACTION, the complex nature of quantifying patient health status certainly allows for the possibility of residual confounding. These clinical variables are based on prior analyses, 22 and some variables may be collinear with KCCQ. Lastly, our findings are exploratory in nature, and we did not adjust for multiplicity of statistical testing.
After adjustment for clinical variables, changing health status did not have a linear relationship with clinical outcomes. As reported by the KCCQ scale, worsening patient-reported health status and improvements in KCCQ up to 8 points was associated with risk of future clinical events in patients with HF. These results affirm the use of KCCQ as a clinical tool to monitor changes in health status in HF patients. Further investigation is still needed to understand the best clinical and research utility for these complex measures.
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